Related Experiment Video

Updated: Aug 17, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

HDL-C and the diabetic patient: target for therapeutic intervention?

Robert S Rosenson1

  • 1Preventive Cardiology Center, Northwestern University, The Feinberg School of Medicine, 201 East Huron Street, Galter Pavilion Suite 11-120, Chicago, IL 60611, USA. r-rosenson@northwestern.edu

Diabetes Research and Clinical Practice
|June 15, 2005
PubMed

Insights

Low high-density lipoprotein cholesterol (HDL-C) is linked to metabolic syndrome and type 2 diabetes. Rosuvastatin effectively increases HDL-C, offering potential benefits for cardiovascular health in these patients.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Low high-density lipoprotein cholesterol (HDL-C) is a hallmark of metabolic syndrome and type 2 diabetes.
  • Reduced HDL-C levels correlate with elevated cardiovascular disease risk.
  • Metabolic syndrome and type 2 diabetes often involve abnormal lipoprotein profiles, including increased atherogenic small low-density lipoprotein (LDL) particles.

Purpose of the Study:

  • To evaluate the efficacy of statins in modifying HDL-C levels.
  • To compare the HDL-C raising effects of rosuvastatin with other statins.
  • To determine the potential benefits of agents that increase HDL-C in patients with metabolic syndrome and type 2 diabetes.

Main Methods:

  • Comparative analysis of statin effects on HDL-C levels.
  • Review of clinical data on lipid-modifying drug efficacy.
  • Assessment of lipoprotein sub-class profiles in metabolic syndrome and type 2 diabetes.

Main Results:

  • Rosuvastatin demonstrates comparable or superior HDL-C raising effects compared to atorvastatin, pravastatin, and simvastatin.
  • Statins exhibit varied impacts on HDL-C levels in addition to their LDL-C lowering effects.
  • Abnormal lipoprotein profiles, characterized by excess small LDL particles, are prevalent in metabolic syndrome and type 2 diabetes.

Conclusions:

  • Selecting statins that effectively increase HDL-C, such as rosuvastatin, may be advantageous for managing cardiovascular risk in patients with metabolic syndrome and type 2 diabetes.
  • Comprehensive lipid management, addressing both LDL-C and HDL-C, is crucial for this patient population.
  • Further research into the specific benefits of rosuvastatin on HDL-C in metabolic syndrome and type 2 diabetes is warranted.

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is based on...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...